A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer

Charles Coombes, R.; Hall, Emma; J. Gibson, Lorna; Paridaens, Robert; Jassem, Jacek; Delozier, T.; E. Jones, Stephen; Álvarez, Isabel; Bertelli, Gianfilippo; Ortmann, Olaf; S. Coates, Alan; Bajetta, Emilio; Dodwell, David; E. Coleman, Robert; Fallowfield, Lesley; Mickiewicz, E.; Andersen, Jørn; Eystein Lønning, Per; Cocconi, Giorgio; L. Stewart, Alan; Stuart, Nick; Snowdon, Claire; Carpentieri, M.; Massimini, Giorgio; M. Bliss, Judith

doi:10.1056/nejmoa040331

Public

A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer

Published in New England Journal of Medicine • Mar 10, 2004

Authors:

R. Charles Coombes

Emma Hall

Lorna J. Gibson

Abstract

BACKGROUND: Tamoxifen, taken for five years, is the standard adjuvant treatment for postmenopausal women with primary, estrogen-receptor-positive breast cancer. Despite this treatment, however, some patients have a relapse. METHODS: We conducted a double-blind, randomized trial to test whether, afte...

Subject

Exemestane

Medicine

Tamoxifen

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!